EKR Therapeutics chairman Rolf Classon resigns

Rolf A. Classon, chairman of the board and independent director of EKR Therapeutics, a privately held specialty pharmaceutical company, has resigned effective immediately and will not stand for re-election, according to a press statement from the company.

The resignation comes just five months after Classon joined the specialty pharmaceutical company focused on providing acute-care specialty products, according to the statement.

Classon is an operating partner with Health Evolution Partners, which invests in rapidly growing companies in the health care sector, and has held senior roles at Pharmacia Biosystems, Miles Diagnostics, Bayer and Hill-Rom. As of May, he was a director of Auxilium Pharmaceuticals, Hill-Rom Holdings Inc., Tecan Group Ltd., Prometheus Laboratories and Fresenius Medical Care.

John Bailye, CEO of EKR said when Classon joined the Bedminster, New Jersey, company stated at the time: “We are most fortunate to add Rolf to our board. His rich experience and his ability to apply this to operational and strategic issues alike makes him extraordinarily valuable to our company. With Rolf’s addition, we are further prepared for substantial growth.”

The company did not return calls for comment.